← All trials
NCT05744115
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2021
- Primary completion
- Apr 14, 2022
- Completion date
- Apr 14, 2022
- First posted
- Feb 24, 2023
- Last posted
- Feb 24, 2023
- Enrollment
- 38
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Truman Medical CenterLead sponsor
- Truman Medical CenterCollaborator
- Truman Medical CenterSponsor investigator
- University of MissouriCollaborator
- TelixCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.